Leukaemia Research Fund Centre Institute of Cancer Research Chester Beatty Laboratories London, UK
a.zelent@icr.ac.uk
The ability of all-trans-retinoic acid to stimulate granulocytic differentiation makes it useful in the treatment of acute promyelocytic leukemia. Recent findings suggest that this drug can also induce post-maturation apoptosis through the Apo-2L/TRAIL death ligand (pages 680−686).
